Customers

Hiroshima University Hospital press release – an announcement from our customer-partner   Hiroshima University Hospital established its Epilepsy Center in January 2014. The Epilepsy Center has since been responsible for providing tertiary medical care as part of the...

A 15,000-square-foot neuroimaging suite that includes four high-tech imaging machines — including one of just three in the Southeast — opened Monday as the Norman Fixel Institute for Neurological Diseases at UF Health moves into a new phase of its growth.

Earlier this year, as part of its commitment to continually improving its customer service, MEGIN partnered with B2B international – a full-service market research company, to issue a global satisfaction survey to its customers, looking closely at the service MEGIN...

MEGIN is delighted to be among the delegates of leading UK innovators heading to California this week (12-16 September 2022) as part of ABHI’s mission to bolster trade partnerships and promote the strengths of UK HealthTech stateside. The visit builds on the successes...

This month, MEGIN is delighted to be among the delegate of leading UK HealthTech innovators heading to Tennessee to strengthen trade links and showcase their products and services to the US market. The visit marks the second major US trade mission organised this year...

MEGIN is excited to be among the delegate of pioneering HealthTech companies heading to Texas as part of the first major US trade mission organized by the Association of British HealthTech Industries (ABHI) since the COVID-19 pandemic. The visit marks the launch of a...

HELSINKI, FINLAND (March 07, 2022) - MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX™ neo, by the University of Nebraska Medical Center (UNMC). UNMC scientists and clinicians are at the leading...

It’s a first in Switzerland: the Human Neuroscience Platform (HNP) will host a magnetoencephalography (MEG) facility next summer with the purchase of a MEGIN TRIUX™ neo, a state-of-the-art scanner that allows non-invasive analysis of brain activity. This acquisition is the result of a partnership between several institutions located at the Campus Biotech and promises new breakthroughs in the understanding and treatment of brain disorders such as Alzheimer’s, epilepsy or aphasia.

HELSINKI, FINLAND (January 27, 2022) - MEGIN is pleased to announce the sale of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX™ neo, to the Norman Fixel Institute for Neurological Diseases at University of Florida Health (UF Health). The...

MEGIN is delighted to be joining the Association of British HealthTech Industries (ABHI) UK Pavilion at Arab Health 2022, which is taking place from 24- 27 January in Dubai. The exhibition – the largest event of its kind in the Middle East – will showcase more than...